The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Background: Chronic spontaneous urticaria (CSU) is a clinical condition that affects patients quality of life. Omalizumab is preferred in antihistamines resistant CSU cases. Urticaria activity score-7 ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Skin and mucosal involvement was present in 21 patients (84%) with recurrent episodes of maculopapular skin rash, urticaria and minor oral aphthosis. Giant oral ulcers were reported rarely (2 patients ...

HealthDay News — For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton’s tyrosine ...

She was then on the administration of omalizumab subcutaneously at 300mg/day at a four-week interval. After 4 cycles of omalizumab treatment, oral tripterygium wilfordii tablets was tapered gradually ...

The patient was diagnosed with nonimmunologic contact urticaria from curcumin. Her employment duties were modified so that she could avoid the powder, and her symptoms improved, but she could ...